Concepedia

Author

Robert Hirten

Icahn School of Medicine at Mount SinaiORCID

Also Known As

Montserrat Rivero Tirado, R Hirten, R P Hirten, R. Hirten, R. P. Hirten, Robert Hirten, Robert P Hirten, Robert P. Hirten

152

Publications

3.1K

Citations

29

H-Index

64

Concepts

All Affiliations

Icahn School of Medicine at Mount SinaiCleveland ClinicMontefiore Medical CenterUniversity of California San DiegoNew York University
RH

About

Robert Hirten is an author at Icahn School of Medicine at Mount Sinai specializing in gastroenterology, medicine, and surgery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

335

2

Engineering

3

3

81

3

Public Health

3

3

90

4

Health Sciences

1

1

31

5

Social Sciences

1

1

32

Robert Hirten

×

43

Publications

2K

Citations

25

H-Index

YearCitations

Gut microbiota density influences host physiology and is shaped by host and microbial factors

Eduardo J. Contijoch, Graham J. Britton, Chao Yang,

eLife

2019

172

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

Neeraj Narula, Farhad Peerani, Joseph Meserve,

The American Journal of Gastroenterology

2018

171

Use of Physiological Data From a Wearable Device to Identify SARS-CoV-2 Infection and Symptoms and Predict COVID-19 Diagnosis: Observational Study

Robert Hirten, Matteo Danieletto, Lewis E. Tomalin,

Journal of Medical Internet Research

2021

169

Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn’s Disease

Parambir S. Dulai, Brigid S. Boland, Siddharth Singh,

Gastroenterology

2018

140

Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis

Parakkal Deepak, Quazim A. Alayo, Aava Khatiwada,

Clinical Gastroenterology and Hepatology

2020

103

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases

Joseph Meserve, Satimai Aniwan, Jenna L. Koliani‐Pace,

Clinical Gastroenterology and Hepatology

2018

81

Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis

Parambir S. Dulai, Siddharth Singh, Niels Vande Casteele,

Clinical Gastroenterology and Hepatology

2020

76

Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease

Eugenia Shmidt, Gursimran Kochhar, Justin Hartke,

Inflammatory Bowel Diseases

2018

74

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease

Matthew Bohm, Ronghui Xu, Yiran Zhang,

Alimentary Pharmacology & Therapeutics

2020

68

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease But Not Ulcerative Colitis

David M. Faleck, Adam C. Winters, Shreya Chablaney,

Clinical Gastroenterology and Hepatology

2019

67

Page 1